5 / 5
Volume 8, Issue 2 (Suppl)
J Cytol Histol, an open access journal
ISSN: 2157-7099
Cytopathology 2017
June 21-22, 2017
Page 27
Notes:
conference
series
.com
June 21-22, 2017 Philadelphia, USA
3
rd
International Conference on
Cytopathology & Histopathology
James P Basilion, J Cytol Histol 2017, 8:2 (Suppl)
DOI: 10.4172/2157-7099-C1-010
Defining the cutting edge: The use of molecular imaging to define tumor margins
A
challenge for surgical removal of cancer is to maximize the removal of the cancerous tissue while minimizing removal of
normal tissues. This is critical for a number of prevalent cancers. Several investigators have shown the utility of systemically
delivered optical imaging probes to image tumors and guide surgical removal in small animal models of cancer and recently
first-in-man studies have demonstrated feasibility in Europe. However, to date there are no FDA approved cancer-selective
optical imaging probes that can be used to guide surgery. The future direction of this field is to develop and translate into
clinical use effective optical imaging probes for real-time assessment of surgical margins during tumor resection. Here we
demonstrate a method for imaging tumors margins during surgery that may impact patients in the next few years. Specifically,
we show that optical imaging probes topically applied ex vivo to resected tumor and surrounding normal tissue can rapidly
differentiate between tissues. In contrast to systemic delivery of optical imaging probes which label tumors uniformly over
a long period of time (i.e., hours), topical probe application results in rapid and robust probe activation that is detectable as
early as 5 minutes following application. Importantly, labeling is primarily associated with peri-tumor spaces, defining tumor
margins. This methodology provides a means for rapid visualization of tumor and potentially infiltrating tumor cells and has
potential applications for directed surgical excision of tumor tissues. This technology could find use in surgical resections for
any tumors having differential regulation of cysteine cathepsin activity.
Biography
James P Basilion has obtained his PhD in Molecular Pharmacology from the University of Texas, USA, Postdoctoral studies at the NIH (NICHD) with Dr. R. Klausner.
He had a short stent in industry and then became an Assistant Professor of Radiology at Harvard Medical School and Massachusetts General Hospital. Currently,
he is a full tenured Professor at Case Western Reserve University, Vice-Chair for Basic Research at the Department of Radiology, Director of the Case Center
of Imaging Research, Director of the NFCR Center for Molecular Imaging at Case and Co-Director of the Cancer Imaging Program for the Case Comprehensive
Cancer Center. He is also the President elect for the World Molecular Imaging Society.
james.basilion@case.eduJames P Basilion
Case Western Reserve University, USA